Pain Therapeutics resubmits NDA for REMOXY® ER, an abuse-deterrent, ER drug candidate
Pain Therapeutics announced the resubmission to the FDA of a NDA for REMOXY® ER, its lead drug candidate. The Company expects a six-month review cycle by FDA. Pain Therapeutics developed REMOXY ER as an abuse-deterrent, extended-release, capsule formulation of oxycodone. February 13, 2018